The sector is pretty weak, which is a continuation of the past couple of days. It is not immediately clear to me the reason for the weakness as earnings have.
The sector was a strong performer after the bell but it did not seem to last long. The sector should be strong given the bulk of the earnings but I.
The market looks bad and it is bringing down the sector although I think BIIB has done a pretty good job at reversing some bullish biotech sentiment. That being said.
Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three.
Unlike earlier this week where bad news was shrugged off, it looks like we are going to see selling on the bad news. This pullback should eventually generate nice bargains.
A good start to the day with earnings almost universally beats and raises. Given the strength the sector showed yesterday, this should move the group higher and increase expectations for.
The sector is a little weak this morning, which is to be expected but not nearly as weak as I thought it would be going into the open. There has.
There is some news this morning but nothing that in and of itself is likely to move the sector. On the other hand, the news has generally been positive, so.
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat”.
We end one macro crisis and head directly into another. China, however, is more important than Greece so this makes a little more sense but even this selling is likely.
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.
There is a little more news today but still relatively quiet. The market seems to be looking for a direction but the sector seems to be outperforming to the upside..
This is the last note before the fourth and I wanted to spend time going into a new therapeutic space and highlight a new company (well, it is new to.
The summer is seasonally weak, especially after the EHA and ASCO- right? I am not sure of the exact catalyst for the move today but it is certainly moving the.
Market doing a little better but biotechs seemed to take yesterday off despite the broader rally. The sector seems to be more positive today (there were certainly bright spots yesterday.
The market is quite resilient. While we did not get a full reversal yesterday, the market came back and biotechs seemed to outperform. This morning is off to a good.
Mannkind, the maker of the inhaled insulin product Afrezza, is the 11th best performing biotech stock according to Finviz in the last month, up 62%. That performance is in line.
This is sort of a different start to the day with the market off to a good start but biotechs the obvious laggard. The sector had been one of the.
The sector is quiet and macro seems neutral if not slightly negative but it is early. There is not a lot of news to discuss. I suspect that the trend.
The sector is not doing great but also not significantly pulling back (broader market is lower but also pretty choppy). The large caps appeared weak again and this is still.